| 证券代码 | GWPH.O |
| 证券名称 | GW Pharmaceuticals plc ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-05-01 |
| 首发价格(元) | 8.9 USD |
| 首发数量(股) | 3500000 |
| 首发募资额(元) | 31,150,000.00 USD |
| 首发主承销商 | Cowen and Company, LLC,Lazard Capital Markets LLC |
| 货币单位 | USD |
| 公司名称 | GW Pharmaceuticals plc |
| 注册地址 | 英格兰和威尔士 |
| 办公地址 | Sovereign House, Vision Park, Chivers Way, Histon, Cambridge, United Kingdom |
| 成立日期 | 1998 |
| 董事会主席 | - |
| 公司属地 | United Kingdom 英国 |
| 公司网址 | www.gwpharm.com |
| 电话 | +44 (012) 2326-6800 |
| 传真 | +44 (012) 2323-5667 |
| 公司简介 | GW Pharmaceuticals plc ("GW") has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. GW successfully developed the world’s first prescription medicine derived from the cannabis plant, which is now approved in numerous countries outside of the United States for the treatment of spasticity due to multiple sclerosis. GW is also developing a liquid formulation of purified cannabidiol (CBD), also known as Epidiolex in the US, (investigational only and not approved for use at this time) for the treatment of seizures in certain rare and severe early-onset, drug-resistant epilepsy syndromes. The company has a deep pipeline of additional clinical stage cannabinoid product candidates for both orphan and non-orphan indications with a particular focus on neurological conditions. GW Pharmaceuticals was founded in 1998 and is listed on the NASDAQ Global Market (GWPH). The company has operations in both the US and the UK. |